News | Radiation Therapy | July 03, 2017

IBA and Philips Step Up Commercial Collaboration in Brazilian Proton Therapy Market

Companies plan to escalate joint sales and marketing activities in the region

IBA and Philips Step Up Commercial Collaboration in Brazilian Proton Therapy Market

July 3, 2017 — IBA and Philips announced in mid-June they are stepping up their combined effort for proton therapy in Brazil.

Both companies agreed to escalate joint sales and marketing activities in Brazil, for the promotion of Philips's imaging and clinical informatics solutions in oncology, and IBA's proton therapy solutions. The agreement merges their respective expertise in image guidance and therapy with the ultimate objective of enabling more effective and personalized cancer care.
 
The Brazilian market for superior medical imaging solutions and advanced forms of radiotherapy treatment such as proton therapy is a key focus for both partners. The commercial collaboration between Philips and IBA has already led to the successful execution of proton therapy contracts in Europe, Asia and the Middle-East.
 
The two companies offer unique integrated solutions for proton therapy and molecular imaging centers. They are currently installing state-of-the-art proton therapy solutions at three compact proton therapy centers in the U.K., one compact center in the Middle East, and one large proton therapy center in India. Depending on the proton therapy center, the installed solution can include IBA’s proton therapy systems, such as; the Proteus One and Proteus Plus, and Philips’ imaging and clinical informatics solutions, such as Philips’ Big Bore CT (computed tomography) and positron emission tomography (PET)/CT systems and Philips’ Pinnacle3 Treatment Planning System.

For more information: www.iba-worldwide.com, www.usa.philips.com/healthcare

Related Content

New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA
News | Proton Therapy | June 14, 2019
IBA announced the physics team of University Medical Center Groningen (UMCG) in the Netherlands has developed and...
ASTRO Applauds New Prior Authorization Legislation
News | Radiation Therapy | June 07, 2019
The American Society for Radiation Oncology (ASTRO) released a statement applauding Congress’s introduction of...
IBA Dosimetry Launches myQA iON
News | Quality Assurance (QA) | June 07, 2019
IBA (Ion Beam Applications S.A.) announced the launch of myQA iON at the 2019 Particle Therapy Co-Operative Group (...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...
A set of synthetic CT images created from T1 and T2 weighted MR imaging of a prostate/rectum phantom at Henry Ford Hospital. The hospital is one of the research centers developing  synthetic CT imaging for treatment planning to avoid the need for CT scans of a patient just for treatment planning purposes when they already have a more detailed soft tissue MRI exam of  the anatomy.

A set of synthetic CT images created from T1 and T2 weighted MR imaging of a prostate/rectum phantom at Henry Ford Hospital. The hospital is one of the research centers developing synthetic CT imaging for treatment planning to avoid the need for CT scans of a patient just for treatment planning purposes when they already have a more detailed soft tissue MRI exam of the anatomy.

Feature | Radiation Oncology | May 29, 2019 | By Jeff Zagoudis
Accuray Radixact

Accuray Radixact

Feature | Radiation Therapy | May 29, 2019 | By Jeff Zagoudis
While radiation therapy as a disciplin
Sponsored Content | Case Study | Radiation Therapy | May 29, 2019
The so-called “Grey Tsunami” of baby boomers using healthcare services isn’t taking the Radiation Medicine Program at